| Market Cap | 6.65M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.87M | Forward P/E | -0.79 | EPS next Y | - | 50D Avg Chg | 5.00% |
| Sales | 82.43k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -68.00% |
| Recommedations | 2.00 | Quick Ratio | 0.30 | Shares Outstanding | 41.66M | 52W Low Chg | 114.00% |
| Insider Own | 7.83% | ROA | -182.75% | Shares Float | 34.73M | Beta | 2.83 |
| Inst Own | 5.77% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.19 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 16,559 | Target Price | - |
| Oper. Margin | -5,297.30% | Earnings Date | - | Volume | 6,290 | Change | -10.51% |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary Sketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; and with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
